Business Context and Reporting Period
This Form 6-K filing by Sanofi-Aventis (formerly Sanofi-Synthelabo) is dated October 8, 2004. The report discloses a joint press release with Procter & Gamble (P&G) regarding the strengthening of their strategic alliance on the osteoporosis drug Actonel (risedronate sodium tablets). Sanofi-Aventis is identified as the world's third-largest pharmaceutical company and the number one pharmaceutical company in Europe.
Key Financial Metrics
- Actonel Sales: For the twelve-month period ending June 30, 2004, total global sales exceeded $1 billion.
- Actonel Growth: Sales increased over 65% compared to the previous year.
- Oral Health Brands: The Fluocaril and Parogencyl brands represented sales of less than 55 million euros in 2003.
- Other Metrics: The filing text does not provide clear values for Sanofi-Aventis' consolidated revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Strategic Developments
- Alliance Agreement: Sanofi-Aventis and P&G signed an agreement to maintain their collaboration on Actonel, enhancing its global market presence. P&G will jointly promote the drug in additional territories.
- Brand Option: P&G was granted an option to acquire certain oral health care brands (Fluocaril and Parogencyl) from Sanofi-Aventis.
- Supply Contract: An exclusive supply contract for a 5-year period was entered into to preserve employment within Sanofi-Aventis related to the oral health brands.
Guidance, Outlook, and Risks
Management believes the new agreement will enhance the global market presence of Actonel and formalize a common commitment to research, development, and commercial efforts. The filing includes standard forward-looking statements regarding future operations and performance, noting that actual results may differ due to various risks.
Identified risks include regulatory, tax, and legal matters (including product liability), currency fluctuations, raw material price increases, and global political or economic uncertainty. Sanofi-Aventis explicitly states it does not undertake any obligation to update forward-looking information other than as required by law.
Investor Verification Checklist
- Verify the specific terms of the option granted to P&G regarding the acquisition of Fluocaril and Parogencyl brands.
- Confirm the exact financial impact of the Actonel alliance on Sanofi-Aventis' consolidated revenue in upcoming quarters.
- Review the 5-year exclusive supply contract details to understand the long-term revenue stream from the oral health brands.
- Consult the most recent Form 20-F for comprehensive risk factors and consolidated financial statements not detailed in this 6-K.